XCell ATF Technology

XCell ATF^® intensification solves upstream manufacturing capacity, productivity, and throughput challenges.

intensification Delivers more Product Faster

XCell ATF^® technology helps simplify and intensify upstream processes to deliver more product, faster. Intensified processes achieve higher cell densities, require smaller bioreactors and consume less suite time. Increase throughput, productivity, and capacity in both clinical and commercial manufacturing.

DELIVER MORE, FASTER

Increase throughput
More programs, more molecules

Increase productivity
More product per batch

Increase capacity 
More batches per facility

Execute high roi BUSINESS DECISIONS

Reduce bioreactor size up to 10 fold
For example from 10,000 L to 1,000 L

Advance your program
Smaller, flexible intensified processes

Re-think your facility
Lower cost, lower risk, faster results

XCell ATF^®, a leading cell retention technology, simplifies and fast-tracks upstream intensification development for gene therapy, fed-batch intensification, seed train intensification, perfusion, and media exchange applications.

XCell ATF^® by application

FED-BATCH

INTENSIFICATION

N-1 Perfusion

High Productivity Harvest

PERFUSION

Long-term perfusion

N-1 with Perfusion

SEED TRAIN

INTENSIFICATION

N-1 Intensification

N-2 or earlier Intensification

LVHD Frozen Process Intermediates

XCell ATF^® intensification from Process development to manufacturing

The XCell ATF^® intensification simplifies and fast-tracks upstream intensification development from PD to commercial scale. Intensification increases throughput, accelerates tech transfer and optimizes your process in clinical manufacturing and MSAT while increasing bioreactor productivity and reducing costs in commercial manufacturing. Higher productivity, smaller bioreactors and higher throughput with shorter times to harvest, combine to mitigate facility expansion risks and capital costs.

XCell Atf^® in Gene Therapy

The XCell ATF^® solution delivers an efficiency boost both pre- and post-transfection in the gene therapy workflow. Increase yield and save time during host cell expansion and pre-transfection preparation. Post-transfection options exist for multiple host types. Learn more about Gene therapy solutions at,  Gene Therapy Manufacturing 2.0 

Lentivirus Production

Boost output
Eliminate centrifugation
Reduce depth filtration requirements

AAV Production

Boost output
Save time

Adenovirus and Vaccine Production

Boost output
Produce clarified harvest
Go straight to downstream

Xcell ATF^® Insect Line Delivers 10x VCD and Lowers cogs

Source: ExpreS²ion Technologies

Higher productivity and lower COGs for malaria therapeutic candidate.

10X VCD more than 2-week Fed- Batch (350 x 10⁶cells/mL)
50% decrease in bioreactor time
20-fold increase in yield

How XCell ATF^® Technology works

The XCell ATF^® System is based on award-winning alternating tangential flow (ATF) technology, created by the action of a diaphragm moving upward and downward within a pump head, connected to a filter housing and attached to a bioreactor. Alternating tangential flow is attained by the action of a diaphragm pump.

XCell ATF^® Devices and controllers

The XCell ATF^® System delivers a complete solution for upstream intensification with robust hardware software integration. Available in single-use and stainless steel formats with sizes from lab-scale (2 L) to process scale (5000 L). Each system consists of an XCell ATF^® Device, XCell™ controller, software, tubing and sensors.

Devices by scale

Devices by format

Controllers

Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.

about repligen manufacturing